Sign In
Buy MDWD
$14.12
+0.0200 (+0.142%)
At Close: Jul 31, 2026
MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript
01:31pm, Thursday, 14'th Aug 2025
MediWound Ltd. (NASDAQ:MDWD ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Barry J.
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
09:11am, Thursday, 14'th Aug 2025
MediWound (MDWD) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.68 per share a year ago.
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Thursday, 14'th Aug 2025
VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid ® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Stra
MediWound Announces New EscharEx ® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
MediWound to Report Second Quarter 2025 Financial Results
07:30am, Monday, 04'th Aug 2025
MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd.
MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript
12:46pm, Wednesday, 21'st May 2025
MediWound Ltd. (NASDAQ:MDWD ) Q1 2025 Earnings Conference Call May 21, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Ofer Gonen - CEO Hani Luxenburg - CFO Barry Wolfenson - EVP of
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
09:11am, Wednesday, 21'st May 2025
MediWound (MDWD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.39 per share a year ago.
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Wednesday, 21'st May 2025
VALUE Phase III trial of EscharEx ® in venous leg ulcers advancing as planned NexoBrid ® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue o
MediWound Ltd.: Undervalued High-Growth Potential
10:34am, Friday, 16'th May 2025
I rate MediWound a buy due to strong revenue growth, a robust pipeline, and significant undervaluation with massive upside potential. NexoBrid's commercial success and orphan drug status drive revenue
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
07:30am, Tuesday, 13'th May 2025
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL® Post hoc analysis published in the peer-
MediWound to Report First Quarter 2025 Financial Results
08:00am, Monday, 05'th May 2025
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
08:00am, Monday, 28'th Apr 2025
Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL ® , and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study
MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript
12:10pm, Wednesday, 19'th Mar 2025
MediWound Ltd. (NASDAQ:MDWD ) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chie
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
09:10am, Wednesday, 19'th Mar 2025
MediWound (MDWD) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.19 per share a year ago.
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
07:00am, Wednesday, 19'th Mar 2025
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for
